Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04764929
Other study ID # AAAT5640
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 7, 2021
Est. completion date September 2022

Study information

Verified date March 2022
Source Columbia University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This a research study to find out whether giving Continuous Positive Airway Pressure (CPAP) through a Helmet is the same or better than giving CPAP through a Facemask, Nasal Mask, or Nasal Prongs. CPAP can help kids with lung infections breathe easier. The machine delivers pressurized air, which may help people with lung infections breathe more easily. Doctors routinely use a Facemask, Nasal Mask or Nasal Prongs to give CPAP for kids with lung infections, but the researchers want to know whether using Helmet CPAP is the same or better.


Description:

Prior clinical trials have demonstrated efficacy of Helmet CPAP in adults with acute respiratory distress syndrome, superior tolerance and improved respiratory scores compared to nasal/facial CPAP in infants, and no major safety concerns were identified with the use of helmet CPAP. This is a prospective pilot study to (1) determine if infants and pediatric patients requiring CPAP in the PICU will tolerate helmet CPAP for at least four hours, and (2) measure changes in the respiratory rate, oxygen saturation, heart rate and blood pressure over four hours. If helmet CPAP is found to be well tolerated in this small cohort, a larger study comparing it directly to other CPAP interfaces will be conducted.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 2022
Est. primary completion date July 2022
Accepts healthy volunteers No
Gender All
Age group 1 Month to 5 Years
Eligibility Inclusion Criteria: - One month to 5 years of age (inclusive) admitted to the PICU with community acquired pneumonia or bronchiolitis, having been stable on nasal or facemask CPAP for at least four hours but less than 48 hours, and parental informed consent. Exclusion Criteria: - Age less than 1 month or greater than 5 years - Positive for COVID-19 - Need for invasive mechanical ventilation or higher levels of non-invasive ventilation such as bi-level positive airway pressure (BPAP) - Unresponsiveness (GCS 8 or less) - Hypotension as defined as a systolic blood pressure less than 5th percentile for age - Existing head or neck trauma, known or suspected air leak syndrome (pneumothorax, pneumomediastinum, subcutaneous emphysema), known or suspected increased intracranial pressure - Non-English speaking parent

Study Design


Intervention

Device:
Helmet CPAP
Vyatil nonpowered oxygen tent system

Locations

Country Name City State
United States Columbia University Medical Center New York New York

Sponsors (1)

Lead Sponsor Collaborator
Patrick Wilson

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tolerability of helmet CPAP Percentage of patients that tolerate helmet CPAP for at least four hours. Tolerance is defined as the successful application and maintenance of helmet CPAP without any unplanned, prolonged (>5 minutes) removals or disruptions. Four hours
Secondary Respiratory rate We will measure respiratory rate in breaths per minute every hour blood pressure every hour for four hours. Four hours
Secondary Heart rate We will measure heart rate in beats per minute every hour Four hours
Secondary Oxygen saturation We will measure pulse oxygen saturation as a percent every hour Four hours
Secondary Systolic blood pressure We will measure systolic blood pressure in millimeters of mercury every hour Four hours
See also
  Status Clinical Trial Phase
Completed NCT04517123 - Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study N/A
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Completed NCT01271842 - Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study N/A
Completed NCT04724538 - Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19 Phase 1/Phase 2
Recruiting NCT04414293 - Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis N/A
Completed NCT04047719 - Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
Recruiting NCT04528888 - Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Phase 3
Completed NCT04606407 - Inhaled NO for the Treatment of Viral Pneumonia in Adults N/A
Terminated NCT04619693 - Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
Recruiting NCT05077917 - Cromolyn Sodium for Treatment of COVID-19 Pneumonia Phase 3
Withdrawn NCT04381923 - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia N/A
Recruiting NCT05976581 - Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients N/A
Active, not recruiting NCT04381364 - Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) Phase 2
Completed NCT04422613 - Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia N/A
Completed NCT04479540 - Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease N/A
Recruiting NCT04474340 - COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients Phase 1
Completed NCT04424836 - HFNC Treatment in COVID-19 Pneumonia
Active, not recruiting NCT04365101 - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 Phase 1/Phase 2
Completed NCT04387799 - Determinants of COVID-19 Pneumonia (MC-19)
Completed NCT04382547 - Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Phase 1/Phase 2